Development of an immune-related prognostic index associated with osteosarcoma

Figures & data

Figure 1. Differentially expressed immune-related genes (IRGs). (a) Heat map. (b) Expression patterns of 29 immune-related genes (IRGs) in nonmetastatic and metastatic osteosarcoma samples. The red dots on the X-axis indicates the metastatic samples and the blue dots indicate the nonmetastatic samples. N, nonmetastatic samples; T, metastatic samples

Figure 2. Results of gene functional enrichment. (a) GO analysis shows the biological processes and molecular functions involved in DIRGs. (b) KEGG pathway analysis of differentially immune-related genes

Table 1. The specific information of IRGs

ID	Description Name	Expression
ITGAL	Integrin, alpha L (antigen CD11A (p180))	Down
CD79A	CD79a molecule, immunoglobulin-associated alpha	Down
PIK3CG	Phosphoinositide-3-kinase, catalytic, gamma polypeptide	Down
TNFSF8	Tumor necrosis factor (ligand) superfamily, member 8	Down
CSF3R	Colony stimulating factor 3 receptor (granulocyte)	Down
MTNR1B	Melatonin receptor 1B	UP
S100A1	S100 calcium binding protein A1	UP
NPPC	Natriuretic peptide precursor C	UP
IGLV1-51	Immunoglobulin lambda variable 1–51	Down

Figure 3. Prognostic value and mutations of IRGs. (a) Forest plot of immune genes related to OS survival. (b) Mutations in prognosis-related IRGs

Figure 4. Immune-related prognostic index (PI) of OS patients. (a) Patient overall survival was notably lower in the high-risk group. (b) The heatmap of the four signature genes expression profiles. (c-d) The distribution of risk scores, patient survival time, and status for OS. (e-f) Univariate and multiple regression analysis of OS and the relationships between risk score, sex, metastasis, and age

Figure 5. The prognostic value of immune-related prognostic index of OS patients. (a) Survival-dependent receiver operating characteristic (ROC) curves for validation of prognostic value of the prognostic index. (b) The nomogram for predicting overall survival

Table 2. Immune-related gene sets that associated with high-risk group

NAME	ES	NES	NOM p-val	FDR q-val
Cell cycle	0.457	1.884	0.012	0.227
Cell adhesion molecules	−0.682	−2.302	0.000	0.002
B cell receptor signaling pathway	−0.645	−2.275	0.000	0.002
Chemokine Signaling Pathway	−0.594	−2.265	0.000	0.002
Cytokine cytokine receptor interaction	−0.601	−2.225	0.000	0.003

ES, enrichment score; NES, normalized enrichment score; NOM, nominal; FDR, false discovery rate.

Figure 6. Enrichment plots of gene ontology annotation between high- and low-risk groups

Figure 7. Evaluation of the proportions of TIICs based on CIBERSORT. (a) The varied proportions of 22 subtypes of immune cells in tumor samples from the high- and low-risk groups. (b) Heatmap of 22 immune-infiltrating cell types in tumor samples

Figure 8. The level of immune cells and Kaplan-Meier analysis in patients with OS. (a) Relationship between the level of CD4 naïve T cells and metastasis. (b) Relationship between the level of T cells CD4 memory activated cells and metastasis. (c) The association between CD4 naïve T cells and overall survival of OS. (d) The association between T cells CD4 memory activated and overall survival of OS

Availability of data and materials

All analyzed data are included in this published article and its supplementary information file. The original data are available upon reasonable request to the corresponding author.